AGN194204

AGN194204 (IRX4204) is an orally active and selective RXR agonist with Kd values 0.4 nM, 3.6 nM and 3.8 nM and EC50s of 0.2 nM, 0.8 nM and 0.08 nM for RXRα, RXRβ and RXRγ, respectively. AGN194204 is inactive against RAR. AGN194204 has anti-inflammatory and anticarcinogenic actions[1][2].

Product Specifications

CAS Number

[220619-73-8]

Product Name Alternative

IRX4204; NRX194204; VTP 194204

UNSPSC

12352005

Target

Apoptosis; RAR/RXR

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/agn194204.html

Purity

99.94

Solubility

DMSO : 35 mg/mL (ultrasonic; warming)

Smiles

O=C(O)/C=C(C)/C=C/[C@H]1[C@](C2=CC=C3C(C)(C)CCC(C)(C)C3=C2)(C)C1

Molecular Formula

C24H32O2

Molecular Weight

352.51

References & Citations

[1]Liby K, et al. A new rexinoid, NRX194204, prevents carcinogenesis in both the lung and mammary gland. Clin Cancer Res. 2007 Oct 15;13 (20) :6237-43.|[2]Vuligonda V, et al. Enantioselective syntheses of potent retinoid X receptor ligands: differential biological activities of individual antipodes. J Med Chem. 2001 Jul 5;44 (14) :2298-303.